Predictive factors for successful imatinib cessation in chronic myeloid leukemia patients treated with imatinib

American Journal of Hematology

Volumn 88, Issue 6, 2013, Pages 449-454

  Lee, Sung Eun ^a   Choi, Soo Young ^a   Bang, Ju Hee ^a   Kim, Soo Hyun ^a   Jang, Eun Jung ^a   Byeun, Ji Young ^a   Park, Jin Eok ^a   Jeon, Hye Rim ^a   Oh, Yun Jeong ^a   Kim, Hyeoung Joon ^b   Kim, Yeo Kyeoung ^b   Park, Joon Seong ^c   Jeong, Seong Hyun ^c   Kim, Sung Hyun ^d   Zang, Dae Young ^e   Oh, Sukjoong ^f   Koo, Dong Hoe ^f   Kim, Hawk ^g   Do, Young Rok ^h   Kwak, Jae Yong ⁱ   Kim, Jeong A ^j   Kim, Dae Young ^k   Mun, Yeung Chul ^l   Mauro, Michael J ^m   Kim, Dong Wook ^a,n   more..

^a The Catholic University of Korea   (South Korea)

^b Chonnam National University   (South Korea)

^c Ajou University School of Medicine   (South Korea)

^d Dong A University College of Medicine   (South Korea)

^e Hallym University College of Medicine   (South Korea)

^f Sungkyunkwan University   (South Korea)

^g University of Ulsan College of Medicine   (South Korea)

^h Keimyung University   (South Korea)

ⁱ Chonbuk National University Medical School   (South Korea)

^j The Catholic University of Korea   (South Korea)

^k University of Ulsan College of Medicine   (South Korea)

^l Ewha Womans University School of Medicine   (South Korea)

^m OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

ⁿ The Catholic University of Korea   (South Korea)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; BCR ABL1 PROTEIN; IMATINIB; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CELL EXPANSION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; FEMALE; FOLLOW UP; HUMAN; MALE; MINIMAL RESIDUAL DISEASE; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; PROBABILITY; PROSPECTIVE STUDY; UNDETECTABLE MOLECULAR RESIDUAL DISEASE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BENZAMIDES; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; YOUNG ADULT;

EID: 84878168513     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23427     Document Type: Article

References (26)

1. Branford S, Seymour JF, Grigg A, et al. BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria. Clin Cancer Res 2007;13:7080-7085.
2. Kim D, Goh HG, Kim SH, et al. Comprehensive therapeutic outcomes of frontline imatinib mesylate in newly diagnosed chronic phase chronic myeloid leukemia patients in Korea: Feasibility assessment of current ELN recommendation. Int J Hematol 2012;96:47-57.
3. de Lavallade H, Apperley JF, Khorashad JS, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: Incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008;26:3358-3363.
4. Okabe S, Tauchi T, Ishii Y, et al. Sustained complete cytogenetic remission in a patient with chronic myeloid leukemia after discontinuation of imatinib mesylate therapy. Int J Hematol 2007;85:173-174.
5. Goh HG, Kim YJ, Kim DW, et al. Previous best responses can be re-achieved by resumption after imatinib discontinuation in patients with chronic myeloid leukemia: implication for intermittent imatinib therapy. Leuk Lymphoma 2009;50:944-951.
6. Kuwabara A, Babb A, Ibrahim A, et al. Poor outcome after reintroduction of imatinib in patients with chronic myeloid leukemia who interrupt therapy on account of pregnancy without having achieved an optimal response. Blood 2010;116:1014-1016.
7. Yhim HY, Lee NR, Song EK, et al. Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response. Leuk Res 2012;36:689-693.
8. Guastafierro S, Falcone U, Celentano M, et al. Is it possible to discontinue imatinib mesylate therapy in Chronic Myeloid Leukemia patients with undetectable BCR/ABL? A case report and a review of the literature. Leuk Res 2009;33:1079-1081.
9. Verma D, Kantarjian H, Jain N, et al. Sustained complete molecular response after imatinib discontinuation in a patient with chronic myeloid leukemia not previously exposed to interferon alpha. Leuk Lymphoma 2008;49:1399-1402.
10. Rousselot P, Huguet F, Rea D, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007;109:58-60.
11. Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: The prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010;11:1029-1035.
12. Melo JV, Ross DM. Minimal residual disease and discontinuation of therapy in chronic myeloid leukemia: Can we aim at a cure? Hem Am Soc Hematol Educ Program 2011;2011:136-142.
13. Takahashi N, Kyo T, Maeda Y, et al. Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia. Haematologica 2011;97:903-906.
14. Nollet F, Billiet J, Selleslag D, et al. Standardisation of multiplex fluorescent short tandem repeat analysis for chimerism testing. Bone Marrow Transpl 2001;28:511-518.
15. Baron F, Sandmaier BM. Chimerism and outcomes after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. Leukemia 2006;20:1690-1700.
16. Sloma I, Jiang X, Eaves AC, et al. Insights into the stem cells of chronic myeloid leukemia. Leukemia 2010;24:1823-1833.
17. Michor F, Hughes TP, Iwasa Y, et al. Dynamics of chronic myeloid leukaemia. Nature 2005;435:1267-1270.
18. Roeder I, Horn M, Glauche I, et al. Dynamic modeling of imatinib-treated chronic myeloid leukemia: Functional insights and clinical implications. Nat Med 2006;12:1181-1184.
19. Kolb HJ, Mittermuller J, Clemm C, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990;76:2462-2465.
20. Michallet AS, Nicolini F, Furst S, et al. Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT). Bone Marrow Transpl 2005;35:601-608.
21. Molldrem JJ, Lee PP, Wang C, et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 2000;6:1018-1023.
22. Kanodia S, Wieder E, Lu S, et al. PR1-specific T cells are associated with unmaintained cytogenetic remission of chronic myelogenous leukemia after interferon withdrawal. PLoS One 2010;5:e11770.
23. Burchert A, Wolfl S, Schmidt M, et al. Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia. Blood 2003;101:259-264.
24. Carella AM. Interferon-alpha is able to maintain complete molecular remission induced by imatinib after its discontinuation. Leukemia 2008;22:1090-1091.
25. Chen CI, Maecker HT, Lee PP. Development and dynamics of robust T-cell responses to CML under imatinib treatment. Blood 2008;111:5342-5349.
26. Burchert A, Muller MC, Kostrewa P, et al. Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia. J Clin Oncol 2010;28:1429-1435.